Novel Approaches to Assessing Cardiac Safety – Proceedings of a Workshop by Katherine Fletcher et al.
Novel Approaches to Assessing Cardiac
Safety – Proceedings of a Workshop
Regulators, Industry and Academia Discuss the Future of In Silico
Cardiac Modelling to Predict the Proarrhythmic Safety of Drugs
Katherine Fletcher,1 Rashmi R. Shah,2,3 Arthur Thomas,2,4 Frank Tobin,2,5 Blanca Rodriguez,1
Gary R. Mirams,1 Javier Saiz6 and Denis Noble,1 on behalf of the preDiCT Project
1 University of Oxford, Oxford, UK
2 Member of the preDiCT Scientific Advisory Board, University of Oxford, Oxford, UK
3 Rashmi Shah Consultancy Ltd, Gerrards Cross, UK
4 Proteus Associates, Oxford, UK
5 Tobin Consulting LLC, Newtown Square, Pennsylvania, USA
6 I3BH-Universitat Polite`cnica de Vale`ncia, Valencia, Spain
1. Current Paradigms: Limitations
Current testing for proarrhythmic potential of
drugs relies on determining their effect on the QT
interval of the ECG. Because QT prolongation is
frequently associated with blockade of the human
ether-a`-go-go related gene (hERG) channel,
the International Conference on Harmonization
(ICH) S7B guideline[1] recommends an hERG
inhibition assay as the first proxy for identifying
such potential risk. Since hERG assays are rela-
tively cheap and rapid, pharmaceutical compa-
nies invariably rely on them for early-stage triage
of new compounds. The TQT (Thorough QT)
study, the backbone of clinical cardiac safety
testing under ICH E14,[2] is a blunt instrument
with a poor positive predictive value. Candidate
compounds suspected or shown to prolong the
QT interval may be rejected out of hand or attract
restrictive labelling.
However, a number of QT-prolonging drugs,
such as sertindole or alfuzosin, appear in these
tests to be proarrhythmic but do not necessarily
lead to arrhythmias. The statistical power of later-
phase clinical trials is generally insufficient to
predict rare but serious proarrhythmic risks that
can have huge public health and economic im-
pacts. Regulatory and postmarketing experiences
have shown that most serious adverse effects ap-
pear only when a large number of patients have
been exposed over long periods of time. In addition,
drugs are capable of proarrhythmic mechanisms
other than those identified by the hERG channel.
Given that the major cost of developing a new
drug accrues during the clinical trials phase, there
would be a huge economic and clinical benefit to
identifying earlier, and more accurately, those
drugs that are likely to cause arrhythmias.
2. The preDiCT Project: Insight into
Mechanisms
The preDiCT project[3] began in June 2008,
with the award of a major 3-year grant from the
European Commission (EC). It is one of several
projects funded by the EC, coordinated by the
Virtual Physiological Human Network of Excel-
lence. The preDiCT project is aiming to develop
the computational infrastructure necessary for
in silico simulation, and ultimately accurate predic-
tion, of the impact of drug candidates on cardiac
electrophysiology. This research will improve our
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understanding of the mechanisms that underpin
not only the prolongation of the QT interval but
also the induction of dangerous arrhythmias (such
as torsade de pointes [TdP]), and propose new
biomarkers and methodologies for the preclinical
assessment of cardiotoxicity. In turn, this will in-
form the need for, and the nature of, clinical data.
These simulations are done at several levels, from
ionic channel and single cardiac myocyte to a
full 3-D human ECG. The project is developing a
Virtual Research Environment for investigating
the safety (and possibly the efficacy) of drugs by
simulating channel-drug interactions. A major
objective has already been met – to enable the
simulation of drug-induced effects on the human
body surface ECG to be performed thousands of
times faster than was possible at the start of the
project.
The project consortium is a mix of academic
and industry partners, including GlaxoSmithKline,
Roche and Novartis as formal partners, with
AstraZeneca, Pfizer and Johnson & Johnson
collaborating on sub-projects. The ultimate goal
is wider acceptance of modelling techniques with-
in the pharmaceutical industry and regulatory
authorities.
The preDiCT project benefits from three
unique strengths. First, the track record of the
preDiCT team in modelling and simulation in
cardiac electrophysiology. Long before the ini-
tiation of the preDiCT project, researchers at the
University of Oxford had demonstrated how
confidence in drug safety predictions can be in-
creased through understanding the mechanisms,
using as an example two recently approved anti-
anginal drugs.[4] For ivabradine, they identified
the I(f) current as its target and showed that
blocking this current would be safe because the
reduction in pacing frequency would be only
modest. With regard to ranolazine, the compu-
tations illustrated why the compound could be
safe by showing that the prolongation of the
repolarization time it induces would not cause
early afterdepolarizations (these are believed to
precede the onset of TdP). Second, the project
includes several teams of biosimulation experts
organized into sevenWorking Groups, each dedi-
cated to specific areas of investigation, and, finally,
the project has a proactive Scientific Advisory
Board that includes a former Senior Clinical As-
sessor of the UK Medicines and Healthcare pro-
ducts Regulatory Agency (MHRA), one current
and one former divisional director of the US
FDA, clinicians and pharmaceutical industry
representatives, all with expertise in drug-induced
QT prolongation.
3. Workshop Engaging Regulators
and Industry
Aworkshopwas convened on 7 and 8 February
2011 in Oxford, bringing together the preDiCT
team, regulators and industry researchers. The ob-
jectives were to discuss the feasibility of in silico
modelling approaches and the achievements of
the preDiCT project, and to gather their advice to-
wards assimilation of simulation into routine regula-
tory activities. Therewere 29 participants, including
representatives of the industry and regulatory
authorities (Health Canada, the US FDA, the UK
MHRA and the Swedish Medical Products Agen-
cy, the later two also representing the European
Medicines Agency [EMA]). The FDA delegation
consisted of seven senior members from different
centers and divisions (via video link).
Arthur Thomas, Co-chair of the preDiCT
Scientific Advisory Board, introduced the Work-
shop with a proposal that in silico modelling
could be thought of as an additional component,
together with the hERG assay and in vivo non-
clinical studies, in the ICH S7B paradigm of in-
tegrated risk assessment. There was unanimous
agreement among the attendees that approaches
beyond a simple reliance on TQT and QT effects
of a drug were necessary to predict risk.
4. Presentations from the preDiCT
Working Groups
4.1 State-of-the-ArtCardiac Electrophysiology
Modelling and Simulation Tools
Javier Saiz described advances in detailed
modelling of drug-ion channel interaction and
the validation of the models at the ionic and cel-
lular level. New models of how different drugs
(cisapride, dofetilide and lidocaine [lignocaine])
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interact with the different states of the channels
have been developed. Using these models it is
possible to observe the time course of current
inhibition when the drug is applied, and to repro-
duce the frequency-dependent effect of some drugs.
For drugs that affect multiple channels, it was
shown that classical approaches such as hERG
inhibition assays can give rise to false positive
(ebastine) and false negative (HMR1556 and JNJ
303) predictions. For these compounds, this new
approach based on simulation of their effect on
QT interval helped to improve prediction of their
cardiotoxicity potential.
Blanca Rodriguez outlined advances used to
create 3-D models of human cardiac electrical
activation. TheWorkingGroup has created a high-
fidelity 3-D rabbit-specific electrophysiologymodel
of the cardiac ventricles, including the specialized
conduction system. Simulations using the rabbit
model yield a realistic activation sequence, similar
to the one recorded in experiments. Furthermore,
the Working Group has produced mathematical
models to simulate drug-induced effects on the
human heart from the knowledge of drug-ion
channel interactions and then predict their effects
on the ECG (and the QT interval) measured on
the surface of the 3-D human torso. The presenta-
tion stressed the importance of using only robust
and tested software (such as the open-source soft-
ware Chaste developed by the preDiCT team) in
order to trust simulation results.
4.2 Improving Prediction of Torsade
De Pointes
GaryMirams presented work undertaken with
project partner GlaxoSmithKline. They are work-
ing to improve the prediction of TdP risk in early
stages of drug development by using mathema-
tical models of single cardiac myocytes to in-
tegrate experimental data on drug block of three
commonly measured ion channels (hERG, Na+
and L-type Ca++). Of the 31 drugs with known
TdP risk, they found that risk classification as
‘safe’ or ‘dangerous’ according to hERG inhibi-
tion alone misclassified nine drugs, while examin-
ing the changes to the whole-cell action potential
correctly classified all but one.
In another presentation, BlancaRodriguez illus-
trated how the Working Group has combined
clinical, experimental and computational investiga-
tions to improve prediction of drug cardiotoxicity
and to find new biomarkers of drug cardiotoxicity.
The ECG still remains the main clinical tool to
detect potentially lethal drug-induced effects. Now,
we can begin to investigate the relationship be-
tween the ECG and the underlying activity of the
heart in silico. This will allow us to gain insight
into their relationship and shed light on the ‘in-
verse problem’ of interpreting ECGs. In vivo
ECG recordings from Pfizer and clinical colla-
borators are analysed for a variety of ECG bio-
markers to determine better ways of predicting
drug cardiotoxicity. Furthermore, detailed investi-
gation of the ionic mechanisms of drug-induced
arrhythmias is performed using the computational
framework developed in preDiCT to inform the
search for new and more specific biomarkers.
5. Workshop Discussion
Following these presentations, workshop par-
ticipants split into breakout groups to discuss the
scientific and technical aspects of future research
and how this approach can be integrated into the
pharmaceutical development pipeline as well as
the regulatory assessment of safety.
Overall, although the regulators still had some
reservations, they responded very positively and
there was broad agreement that this research was
in line with the priorities set by regulatory bodies,
including the FDA Critical Path Initiative[5] and
the EMAThink-TankReport on InnovativeDrug
Development.[6] The FDA Initiative specifically
identifies drug-induced QT prolongation as one of
the areas for active research, recommending that
the clinical risks associated with a small degree of
QTc interval prolongation needs to be fully defined.
The regulators, as well as industry participants,
identified several challenges that remain in achiev-
ing successful validation and regulatory acceptance
of in silico models.
 Further development and validation of the
in silico approaches would necessitate identifi-
cation of specific compounds and protocols
required to establish the predictive power of
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the simulations to meet the standards of the
requirements of regulators and industrial part-
ners. One difficulty foreseen is that, for many
drugs, the only available ion channel data are
for hERG; therefore, it may not be possible to
determine whether a drug has activity at other
channels. Greater collaboration with industri-
al partners was suggested as a way of acquiring
multiple channel data.
 Safety pharmacology assays at present are not
standardized in terms of cell line (CHO or
HEK), tissue, species, pulse protocols, incuba-
tion medium, temperature, etc., and, therefore,
inter-laboratory variability in results is high.
 Safety pharmacology data available frompublic
domain sources are typically summary statistics,
not detailed rawdata, which limits how they can
be applied.
 Formany new drugswith TQT results available,
postmarketing experience is currently insuffi-
cient to comment on their proarrhythmic risk,
whereas for older drugs with well established
risk, satisfactory interval data from clinical trials
or a TQT are usually lacking.
 Raw detailed ECG public data are of limited
value (e.g., data from theCardiac SafetyResearch
Consortium are limited to moxifloxacin).
In brief, regulators and industry would like a
better understanding of the confidence with which
they can rely on the project’s models. To provide
this, researchers require agreed protocols and de-
tailed ion channel data on a range of compounds,
as well as the level of precision desired, the choice
of species, presence or absence of other variables
such as ischaemia and electrolyte imbalance, ex-
perimental conditions, etc. The experimental pro-
tocols proposed will have to be accepted by all
stakeholders since it is not realistic to have dif-
ferent protocols to meet individual requirements.
A useful preliminary step would be the identi-
fication of a list of drugs with multiple ion chan-
nel activities, for which both non-clinical and
clinical data relevant to proarrhythmic safety are
available, with stakeholder (academia, industry,
regulatory agencies) collaboration and agreement.
The selection process should ensure choices of drugs
with mild, moderate and severe proarrhythmic
risk, different types of proarrhythmia risk and dif-
ferent mechanisms of action, in addition to drugs
with a well documented lack of effect on cardiac
electrophysiology. The project team was strongly
encouraged to investigate the possibility of col-
laboration with the International Life Science
Institute–Health and Environmental Sciences In-
stitute (ILSI-HESI; www.ilsi.org), with a view to
accessing their high-quality rich datasets.
Once there is consensus on a standardized ex-
perimental protocol and a list of drugs of interest,
prospective high-quality experiments can proceed
to characterize the effects of these drugs on a
panel of multiple cardiac ion channels, including,
but not limited to, hERG. Additional considera-
tions should include definition of validation cri-
teria and calibration of the in silico models.
Ultimately, it would be necessary to determine
what proarrhythmias in silico models can predict
(just the TdP, or other ventricular tachyarrhythmias
as well) and whether in silico models can quantify
the risk in terms of severity and frequency.
Once these challenges are overcome, many
potential applications were envisaged.
 Resurrecting ‘good’ drugs prematurely culled
at the hERG assay stage. There may be a need
to consider torsadogenicity in terms of patient-
related risk factors to set up profiles of ‘safe’
versus ‘risky’ drug candidates.
 During early-stage investigations, developing
models in tandem with the development of new
compounds, to predict safety concerns.
 Late-stage rescue (models elucidating complex
mechanisms).
 Strengthening a new drug dossier intended for
submission to regulatory authorities.
 New safety/regulatory approaches during eva-
luation of new drugs, such as use of in silico
screening by the regulatory agency to investi-
gate compounds, and/or requiring in silico in-
vestigations as part of routine filings.
 Patient stratification (identifying likely ‘safe’
or ‘at risk’ subgroups for particular drugs, es-
pecially in the context of co-morbidity and co-
medications).
Following this workshop, the attendees pro-
vided additional feedback via an anonymous
questionnaire. Based on the feedback, the project
team intends to write a proposal for future re-
442 Fletcher et al.
ª 2011 Adis Data Information BV. All rights reserved. Drug Saf 2011; 34 (5)
search, and to convene a follow-up meeting to
discuss this proposal. Further details on this will
be available from the preDiCT website.[3]
All tools and models, including the Virtual
Research Environment, will be open-sourced at
the end of the project in May 2011. The project
team may be able to provide training or conduct
additional case studies before then. If you are
interested in using the models and software or
would like to propose their application to a re-
search project, please contact Katherine Fletcher.
Any other comments would also be very welcome.
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